Advertisement
APLM vs HCWB
Which Stock Would AI Choose? Apollomics Inc. (APLM) vs. HCW Biologics Inc. (HCWB) Stock Comparison
Key Takeaways
- Both APLM and HCWB are clinical-stage biopharmaceutical companies with small market capitalizations, limited revenue, and elevated financing risk.
- APLM is an oncology-focused developer centered on vebreltinib, while HCWB pursues immunotherapies for autoimmune and inflammatory diseases led by HCW9302.
- Both names have faced Nasdaq continued-listing requirements and recent capital raises, underscoring shared balance-sheet and going-concern considerations.
- HCWB recorded a licensing-driven quarterly profit, whereas APLM's revenue base remains minimal, reflecting different near-term cash-inflection dynamics.
- Relative performance has been highly volatile for both tickers, driven largely by clinical milestones, financing events, and exchange-compliance headlines rather than fundamentals.
- Explore APLM Major News and APLM Today's Price Move, as well as HCWB Major News and HCWB Today's Price Move, for deeper, continuously updated coverage of each name.
- To see how algorithmic systems are positioning across the market, explore Trending AI Robots.
Introduction
Investors evaluating speculative biotechnology often weigh two competing questions: whether a company has a differentiated clinical asset, and whether it has the cash to reach its next milestone. This stock comparison examines APLM (Apollomics Inc.) and HCWB (HCW Biologics Inc.), two clinical-stage developers that illustrate both sides of that trade-off. Both operate in oncology and immunology, respectively, and both carry the hallmarks of early-stage biotech risk: modest revenue, ongoing capital needs, and Nasdaq listing considerations. Traders drawn to catalyst-driven price swings and investors assessing pipeline value versus balance-sheet strength may find this relative performance review useful for understanding their current market positioning.
APLM Overview and Recent Performance
Apollomics Inc. is a late-stage clinical biopharmaceutical company developing oncology therapies for difficult-to-treat and treatment-resistant cancers. Its lead program, vebreltinib (APL-101), is a selective c-MET inhibitor under evaluation in non-small cell lung cancer and other tumors, with additional preclinical candidates across tumor inhibitors and immuno-oncology.
Recent market activity has been shaped more by financing and listing events than by clinical data. The company received a Nasdaq deficiency notice related to its minimum market value of listed securities, later announced it had regained compliance, and completed a bridge financing followed by a private placement to support working capital. Its independent auditor has also expressed doubt about the company's ability to continue as a going concern. These developments have contributed to pronounced volatility in APLM, with sentiment swinging alongside capital-raising announcements and exchange-status updates rather than steady fundamental progress.
HCWB Overview and Recent Performance
HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics targeting diseases driven by chronic inflammation, including autoimmune conditions, cancer, and senescence-associated disorders. Its lead autoimmune candidate, HCW9302, is an IL-2 fusion protein in Phase 1 study for alopecia areata, with additional earlier-stage programs in T-cell engagers and cell-therapy reagents.
HCWB has delivered a notable near-term contrast to its peer: a worldwide licensing agreement for HCW11-006 generated a significant upfront payment that drove a profitable quarter, although subsequent results returned to a net loss and management has flagged going-concern risk absent further funding. The company has also executed reverse stock splits and regained Nasdaq compliance during the review period. These events have produced sharp, catalyst-driven price moves, with the equity often repricing around financing terms, compliance letters, and pipeline updates rather than sustained revenue growth.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of algorithmic trading systems from a broader library of hundreds of AI trading bots that collectively monitor thousands of different tickers. Rather than listing every available bot, this section highlights only those whose strategies, performance statistics, and risk parameters appear best suited to prevailing market conditions. Each bot operates with its own trading style, timeframe, and set of tickers, so no single system fits every investor. Reviewing the curated list offers a practical starting point for traders interested in systematic, data-driven approaches to market positioning. Explore Trending AI Robots to evaluate current selections and their performance metrics.
Head-to-Head Comparison
The sharpest contrast between these names lies in therapeutic focus and near-term cash dynamics. APLM is concentrated in oncology with a single lead asset and minimal licensing income, making its path forward dependent on financing and clinical execution. HCWB spans immunology and oncology but has demonstrated an ability to monetize its platform through out-licensing, a strategy that has occasionally produced revenue inflections despite still-narrow cash reserves.
On risk factors, the two are more similar than different. Both are micro-cap biotech names with going-concern disclosures, frequent capital raises, and histories of Nasdaq compliance actions, including reverse splits in HCWB's case. Market sentiment for both has been event-driven, with prices responding to financing terms, regulatory letters, and milestone announcements. Sector exposure also differs: APLM's oncology focus ties it to lung-cancer clinical catalysts, while HCWB's autoimmune program and licensing model create a different catalyst calendar. These trade-offs mean the two names often attract different investor profiles despite occupying the same broad risk tier.
Tickeron AI Verdict
Based on observable trend consistency, stability, and catalyst positioning, Tickeron's AI would likely express a cautious relative preference for HCWB. Its demonstrated capacity to generate licensing revenue and its clearer near-term clinical readout for HCW9302 provide more identifiable catalysts than APLM's financing-dependent timeline. However, this is a probabilistic assessment, not a definitive ranking: both stocks exhibit high volatility, thin liquidity, and material balance-sheet risk. Trend signals could shift quickly on any financing, compliance, or clinical announcement for either name.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLM is a Hold and HCWB is a Hold.
APLM's Indicator enters downward trend
The Aroon Indicator for APLM entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator formed such a pattern. In 177 of the 196 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APLM as a result. In 74 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for APLM turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 27 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
APLM moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for APLM crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APLM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where APLM's RSI Oscillator exited the oversold zone, 18 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where APLM advanced for three days, in 140 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
APLM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. APLM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.704) is normal, around the industry mean (3.498). P/E Ratio (-1.287) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.761) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APLM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
HCWB's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for HCWB turned positive on October 19, 2026. Looking at past instances where HCWB's MACD turned positive, the stock continued to rise in 40 of 44 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where HCWB advanced for three days, in 131 of 166 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
HCWB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HCWB as a result. In 89 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HCWB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for HCWB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.252) is normal, around the industry mean (3.498). P/E Ratio (-0.061) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.232) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. HCWB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HCWB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| APLM | HCWB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 75% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 64% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Advances ODDS (%) | 14 days ago 80% | 9 days ago 79% |
| Declines ODDS (%) | 7 days ago 90% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 78% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APLM’s FA Score shows that 0 FA rating(s) are green while HCWB’s FA Score has 1 green FA rating(s).
- APLM’s FA Score: 0 green, 5 red.
- HCWB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APLM’s TA Score shows that 4 TA indicator(s) are bullish while HCWB’s TA Score has 5 bullish TA indicator(s).
- APLM’s TA Score: 4 bullish, 6 bearish.
- HCWB’s TA Score: 5 bullish, 3 bearish.
Price Growth
APLM (@Biotechnology) experienced а -10.66% price change this week, while HCWB (@Biotechnology) price change was -17.39% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
HCWB is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
APLM and
Correlation & Price change
A.I.dvisor indicates that over the last year, APLM has been loosely correlated with SNTI. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if APLM jumps, then SNTI could also see price increases.
| Ticker / NAME | Correlation To APLM | 1D Price Change % | ||
|---|---|---|---|---|
| APLM | 100% | +2.41% | ||
| SNTI - APLM | 47% Loosely correlated | -11.46% | ||
| HCWB - APLM | 45% Loosely correlated | -0.42% | ||
| PRAX - APLM | 39% Loosely correlated | +1.39% | ||
| MGX - APLM | 37% Loosely correlated | -3.01% | ||
| IPHA - APLM | 36% Loosely correlated | +1.33% | ||
More | ||||
HCWB and
Correlation & Price change
A.I.dvisor indicates that over the last year, HCWB has been loosely correlated with APLM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HCWB jumps, then APLM could also see price increases.
| Ticker / NAME | Correlation To HCWB | 1D Price Change % | ||
|---|---|---|---|---|
| HCWB | 100% | -0.42% | ||
| APLM - HCWB | 45% Loosely correlated | +2.41% | ||
| GDTC - HCWB | 35% Loosely correlated | +0.12% | ||
| IVVD - HCWB | 34% Loosely correlated | -3.66% | ||
| GHRS - HCWB | 32% Poorly correlated | +1.56% | ||
| XLO - HCWB | 30% Poorly correlated | -5.22% | ||
More | ||||